CHEK:NSD-Check-Cap Ltd (USD)

COMMON STOCK | Diagnostics & Research | NSD

Last Closing Price

USD 1.26

Change

-0.08 (-5.97)%

Market Cap

USD 0.09B

Volume

1.77M

Average Target Price

USD 2.50 (+98.41%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a disposable system attached to the patient's back via biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis and report generation. The company was founded in 2004 and is based in Isfiya, Israel.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-05-13 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ILMN Illumina, Inc

+0.61 (+0.16%)

USD54.43B 87.11 49.27
IDXX IDEXX Laboratories, Inc

+5.76 (+1.12%)

USD43.69B 65.93 50.99
DXCM DexCom, Inc

-9.52 (-2.85%)

USD32.25B 64.07 83.72
OZON Ozon Holdings PLC

-0.65 (-1.19%)

USD22.21B N/A N/A
EXAS Exact Sciences Corporation

-2.45 (-2.55%)

USD16.46B N/A N/A
ICLR ICON Public Limited Company

+2.82 (+1.26%)

USD11.86B 35.32 24.09
GH Guardant Health, Inc

-4.16 (-3.65%)

USD11.52B N/A N/A
PRAH PRA Health Sciences, Inc

+1.79 (+1.05%)

USD11.02B 52.02 26.60
SYNH Syneos Health, Inc

+0.28 (+0.33%)

USD8.86B 45.20 22.00
NTRA Natera, Inc

+1.76 (+2.02%)

USD7.67B N/A N/A

ETFs Containing CHEK

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Diagnostics & Research)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 173.91% 98% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 173.91% 98% A+ 99% A+
Trailing 12 Months  
Capital Gain 135.56% 81% B- 82% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 135.56% 81% B- 82% B-
Trailing 5 Years  
Capital Gain -95.95% 10% F 2% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -95.95% 10% F 2% F
Average Annual (5 Year Horizon)  
Capital Gain -46.05% 3% F N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.05% 3% F N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 47.73% 64% D 37% F
Risk Adjusted Return -96.49% 2% F 1% F
Market Capitalization 0.09B 24% F 20% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Diagnostics & Research)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.20 89% B+ 92% A-
Price/Book Ratio 6.19 48% F 26% F
Price / Cash Flow Ratio -7.20 63% D 72% C-
EV/EBITDA 0.23 87% B+ 94% A
Management Effectiveness  
Return on Equity -122.47% 20% F 9% F
Return on Invested Capital -123.23% 11% F 6% F
Return on Assets -59.91% 8% F 3% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 1.96 70% C- 61% D-
Short Percent 5.58% 50% F 37% F
Beta 0.25 91% A- 91% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.